apraclonidine has been researched along with Chronic Disease in 6 studies
apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd
apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intraocular pressure was measured by a masked observer, using Goldmann applanation tonometry, before and 1 hour after the treatment." | 6.69 | Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. ( Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR, 1999) |
| "Apraclonidine 1." | 6.69 | Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. ( Chang, FW; Kolin, T; Nishimoto, JH; Tang, IH, 1999) |
| "2% topical medication or the replacement of apraclonidine with brimonidine resulted in a significant decrease in mean intraocular pressure from 20." | 5.09 | Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. ( Cha, SC; Glover, BK; Kim, C; Kim, YY; Nguyen, KD; Shin, DH, 1999) |
| "Apraclonidine effectively lowers IOP associated with open-angle glaucoma or ocular hypertension; these pilot results will need to be confirmed by a larger pivotal study." | 5.07 | Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. ( Chuniaud, M; Demailly, P; Hitchings, RA; Nagasubramanian, S; Pannarale, MR; Parsons, DG; Pecori-Giraldi, J; Stodtmeister, R, 1993) |
| "Intraocular pressure was measured by a masked observer, using Goldmann applanation tonometry, before and 1 hour after the treatment." | 2.69 | Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. ( Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR, 1999) |
| "Apraclonidine 1." | 2.69 | Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. ( Chang, FW; Kolin, T; Nishimoto, JH; Tang, IH, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagasubramanian, S | 1 |
| Hitchings, RA | 1 |
| Demailly, P | 1 |
| Chuniaud, M | 1 |
| Pannarale, MR | 1 |
| Pecori-Giraldi, J | 1 |
| Stodtmeister, R | 1 |
| Parsons, DG | 1 |
| Gross, RL | 1 |
| Pinyero, A | 1 |
| Orengo-Nania, S | 1 |
| Lamberti, G | 1 |
| Pignalosa, B | 1 |
| Fusco, R | 1 |
| Pignalosa, G | 1 |
| Di Govanni, A | 1 |
| Sebastiani, A | 1 |
| Chevrier, RL | 1 |
| Assalian, A | 1 |
| Duperré, J | 1 |
| Lesk, MR | 1 |
| Shin, DH | 1 |
| Glover, BK | 1 |
| Cha, SC | 1 |
| Kim, YY | 1 |
| Kim, C | 1 |
| Nguyen, KD | 1 |
| Nishimoto, JH | 1 |
| Chang, FW | 1 |
| Tang, IH | 1 |
| Kolin, T | 1 |
5 trials available for apraclonidine and Chronic Disease
| Article | Year |
|---|---|
Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clonidine; Double-Blind Method; Drug Administration | 1993 |
Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic | 1997 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrat | 1999 |
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Chronic Disease; Clonidine; Drug Hypersensiti | 1999 |
Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Chronic Disease; Clonidine; Double-Blind Method; | 1999 |
1 other study available for apraclonidine and Chronic Disease
| Article | Year |
|---|---|
Clinical experience with apraclonidine 0.5%.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Cloni | 1997 |